News

Study reinforces inflammation’s role in Parkinson’s development

Microglia-driven inflammation plays an early, key role in the development of neurodegenerative diseases, including Parkinson’s disease, by contributing to the spread of abnormal protein clumps in the brain. That’s according to study results published by a team of South Korean researchers and highlighted by Zyversa Therapeutics, which recently…

Apathy treatment IRL757 found safe in multiple doses

Multiple doses of apathy treatment IRL757 for Parkinson’s disease and other neurological disorders were well tolerated and presented a favorable pharmacological profile in the second part of a Phase 1 trial. This part of the Phase 1 clinical trial (NCT06493045) tested the safety and tolerability of multiple ascending…

Physical challenges, stigma complicate assistive device use

Barriers including physical difficulties and social stigma may affect how people with Parkinson’s disease use assistive devices meant to help facilitate movement and prevent falls, a study found. Parkinson’s patients said physicians prescribing assistive devices helped them overcome stigma or negative associations. Other possible interventions, including education initiatives and…

Montara to develop LRRK2 inhibitor drug for Parkinson’s

The Michael J. Fox Foundation (MJFF) has awarded a $3.3 million research grant to Montara Therapeutics to develop a brain-selective therapy for Parkinson’s disease using the company’s Brainonly platform. As part of the project, Montara will design and develop an LRRK2 inhibitor drug candidate that can reach…